Heartflow

1/ In the "gold rush" of medical AI, many platforms are racing to market. But in cardiology, the difference between a "good guess" and a "clinical standard" is the depth of the data behind it. Here is why data depth is the ultimate competitive differentiator. 👇

Join us in New Orleans for an educational dinner at ACC.26 on Sunday, March 29, at 6:30 p.m. CDT at Generations Hall. Drs. Nihar Desai, Sarah Rinehart, and Ron Blankstein will lead a discussion on how Heartflow Plaque Analysis provides the insights needed for more precise risk assessment and management. Don’t miss out! Reserve your spot now: events.heartflow.com/en/E0aC836/acc… #ACC2026 #PlaqueAnalysis #YesCCT

Heading to New Orleans for ACC.26? Join us for an exciting slate of events designed to transform cardiovascular care and get hands-on experience with AI-driven Heartflow Plaque Analysis and PCI Navigator. We look forward to connecting at booth 1919 to share the latest evidence and discuss the future of non-invasive coronary care: heartflow.com/acc26 #ACC26 #PlaqueAnalysis #yesCCT

@Steelmanmedical @realDaveFeldman Thank you for your support, @Steelmanmedical!

Think you made the right decision here Dave. I hope you will trim out the CLEERLY BS and republish. The world needs to see the truth behind this data. @Heartflow it’s time to shut the door on your competition and help us make CCTA with Heartflow more economically accessible in the Houston area so we can publish more case studies. And congratulations on Amazon picking up The Cholesterol Code! Great start to getting the story out.

Yes, specifically, retraction due to CLEERLY anomalies of the analysis they provided us, and their repeated decline to do a quality control check. @Heartflow has been an entirely different experience— they’ve helped ensure operational blinding, and are more than happy to run reanalyses for quality control* (*Regardless, their dataset does, in fact, match the same patterns of the other analyses within our study, and all those outside our study — ie, regressors, 0 CAC = lower progression, etc)

Heading to New York for NCVH 2026? Join us for a lunch symposium moderated by Dr. Joseph Puma and featuring speakers Dr. Sam Setareh, Dr. Philip Green, and Matthew Erickson on Saturday, March 21, from 11:45 a.m. to 1:00 p.m. EDT. We’ll explore the clinical need to evolve risk assessment through new tools and emerging evidence, and discuss how Heartflow Plaque Analysis and the DECIDE Registry inform management strategies for patients with CAD. The session will also highlight patient populations that may benefit from earlier, more personalized intervention. Don’t miss out! @NCVHonline #ncvhnewyork #PlaqueAnalysis #yesCCT

Thank you for your continued support @HeartDrTiffany

Building on our growing body of evidence, we’re proud to share new data reinforcing the clinical and economic value of AI-powered cardiovascular care across the heart disease continuum. Three presentations at #ACC26 demonstrate that Heartflow’s AI-powered technology predicts MACE, drives superior lipid outcomes, and results in cost-effective care for patients with CAD. In addition, we’ve enrolled the first patient in the NAVIGATE-PCI Registry, the first large-scale study evaluating how CT-guided PCI planning with Heartflow PCI Navigator impacts clinical strategy, procedural efficiency, and physician confidence. Read our press release to learn more: ir.heartflow.com/news-releases/… #PlaqueAnalysis #AIinHealthcare

@FCademartiri “Seeing plaque beats guessing risk,” we couldn’t have said it better ourselves!

🫀📊 Risk factors vs plaque burden: why age beats checklists This large ADVANCE registry analysis tackles a deceptively simple question: how strongly do traditional cardiovascular risk factors (CVRFs) actually relate to coronary plaque burden on CCTA? The answer is more nuanced—and more provocative—than expected . 🔍 What was studied Using AI-enabled quantitative coronary plaque analysis in 4,430 patients undergoing CCTA, the authors examined how diabetes, hypertension, smoking, and hyperlipidemia relate to: total plaque volume (TPV) plaque subtypes (calcified, non-calcified, low-attenuation) 📈 Key findings Patients with CVRFs had higher plaque volumes than those without—but with substantial overlap Age emerged as the dominant driver of plaque burden: strongest predictor of TPV >250 mm³ AUC 0.62 for age alone only modest improvement to 0.69 when adding sex + all CVRFs Male sex and individual CVRFs were independently associated with TPV—but far less than age Plaque composition was surprisingly similar across different CVRF profiles With aging, plaque shifts from non-calcified to calcified—accelerated in the presence of CVRFs 🧠 Why this matters This study challenges a deeply ingrained assumption: that traditional risk factors neatly map onto anatomical disease burden. They don’t. Many patients: develop significant CAD without standard modifiable risk factors share similar plaque phenotypes despite very different risk profiles It reinforces a critical concept: risk scores estimate probability, not biology. 🧩 The bigger picture CCTA doesn’t just “confirm risk”—it reveals disease directly, even when risk scores are low or ambiguous. Quantitative plaque imaging adds context where clinical variables fall short. ⚠️ Important caveats Cross-sectional design, older cohort, binary CVRF definitions, and no outcome analysis—but the signal is consistent and biologically plausible. 🔮 Bottom line 📌 Traditional risk factors matter—but age matters more. 📌 Plaque burden is only modestly explained by CVRFs. 📌 Seeing plaque beats guessing risk. Precision prevention starts with imaging the disease—not just counting risk factors.

After a legendary career, Pro Football Hall of Famer @BUrlacher54 is focused on protecting his heart for the long game. In our GAMEFILM Registry, he gained a better understanding of the unique heart health needs of former professional athletes. Heartflow's AI-powered technology is available to most adults with suspected coronary artery disease, providing personalized insights to help proactively manage cardiovascular health. Learn more at Heartflow.com/BigGame.

@ColletCarlos This is a massive milestone for the field, Dr. @ColletCarlos. The SCAPIS data confirms what we’ve believed: that moving beyond a calcium score to quantify disease provides the precision to manage CAD.

The SCAPIS study published in JAMA ~25,000 🇸🇪 participants, ~8 years follow-up. Adding coronary CT angiography #CCTA plaque information improved event prediction beyond clinical risk and calcium score. This is the first study showing the added value of CCTA on top of the calcium score for risk prediction. 🎯 What to look for: lipidic soft (non-calcified) plaque. 👀 Practical takeaway: Consider a CT angiography for risk stratification on top of the calcium score. Link: jamanetwork.com/journals/jama/… 🎥 Posting my avatar summarizing the study.

If you’re ready to see how CT-guided PCI is transforming procedural planning for coronary interventions, join us at Baylor Scott & White the Heart Hospital in Plano, Texas on March 13-14. The hands-on program is designed to show you how to integrate Heartflow PCI Navigator and advanced imaging into your everyday clinical workflow. This is a great opportunity to learn from Drs. Karim Al-Azizi, @AmroAlsaid and @ESHLOF as they demonstrate how these tools translate into clear, actionable interventional plans. Secure a seat now: web.cvent.com/event/4f30c8f7… @ShockwaveIVL #AIinHealthcare #InterventionalCardiology #PercutaneousCoronaryIntervention

We’re excited to share this episode of the “Donut of Destiny” podcast hosted by @Heart_SCCT. Dr. @RonBlankstein joins host @PraveenRangana9 to discuss how recent @ACCinTouch and @American_Heart statements are redefining the role of advanced plaque analysis in clinical practice. They dive into the growing impact of AI-driven plaque quantification and what the latest clinical evidence means for personalized CAD management. Tune in below to hear the full discussion. #PlaqueAnalysis #SCCT

7/ Bottom Line: When choosing an AI partner for CAD, ask: ✅ How many prospective trials? ✅ How many patients? ✅ Is there a human checking the work? Data depth isn't just a metric—it's patient safety. #aiinhealthcare #yescct

6/ Physiology + Anatomy = Complete Picture Plaque characterization alone (the "What") is only half the story. Heartflow combines that with FFRct (the "So What?") to show how plaque impacts blood flow. You get a validated, physiological, and disease map—not just a set of automated measurements.

1/ In the "gold rush" of medical AI, many platforms are racing to market. But in cardiology, the difference between a "good guess" and a "clinical standard" is the depth of the data behind it. Here is why data depth is the ultimate competitive differentiator. 👇

“[Having this technology] before you enter the room allows you to have the right strategy, with the right equipment, for the right patient.” It’s great to see the clinical community and experts like Dr. Ziad Ali recognize coronary CTA as an essential tool for the modern interventional cardiologist. As clinicians move beyond simple gatekeeping, advanced imaging can support more precise planning for complex procedures.* With PCI Navigator, teams like Dr. Ali’s can access a vital 3D roadmap to lock in their approach before the procedure begins. It’s a powerful shift toward more proactive, data-driven heart care. Read the full article below. cardiovascularbusiness.com/topics/clinica… *Data on file at Heartflow. #PercutaneousCoronaryInterventions #AIinHealthcare

For cardiologists and other clinicians dedicated to fighting CAD, the focus on lifelong heart health extends far beyond February and #AmericanHeartMonth. Prioritizing initial awareness and robust risk assessment is fundamental for managing CAD. These aren't just starting points; they're the bedrock for effective preventative care and long-term management.